{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:02:45Z","timestamp":1783576965068,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.yebeh.2011.08.026","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T23:21:21Z","timestamp":1317424881000},"page":"461-468","source":"Crossref","is-referenced-by-count":10,"title":["Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid"],"prefix":"10.1016","volume":"22","author":[{"given":"Neta","family":"Pessah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Yagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Hen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob A.","family":"Shimshoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Wlodarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Finnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2011.08.026_bb0005","series-title":"Antiepileptic drugs","first-page":"808","article-title":"Valproic acid: clinical efficacy and use in epilepsy","author":"Bourgeois","year":"2002"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0920-1211(01)00203-0","article-title":"Do we need any more new antiepileptic drugs?","volume":"45","author":"Brodie","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0020","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.yebeh.2004.08.021","article-title":"Correlation analysis between anticonvulsant-ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels","volume":"5","author":"Bialer","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-1211(98)00084-9","article-title":"Congenital malformations due to antiepileptic drugs","volume":"33","author":"Kaneko","year":"1999","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0030","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.1840020513","article-title":"Valproate-Induced hepatic injury: analyses of 23 fatal cases","volume":"2","author":"Zimmerman","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0035","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jama.1979.03300110045025","article-title":"A direct hepatotoxic effect of valproic acid","volume":"242","author":"Sussman","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-0773.1991.tb01303.x","article-title":"Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms","volume":"69","author":"Nau","year":"1991","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0045","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(05)70224-6","article-title":"Birth defects after prenatal exposure to antiepileptic drugs","volume":"4","author":"Perucca","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0050","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1111\/j.1528-1167.2006.00846.x","article-title":"Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003","volume":"47","author":"Koenig","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0055","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.2165\/00003495-200767180-00007","article-title":"Management of epilepsy during pregnancy","volume":"67","author":"Battino","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs (AEDs)","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0065","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.1840040610","article-title":"The hepatotoxicity of valproic acid and its metabolism in rats: II. Intermediary and valproic acid metabolism","volume":"4","author":"Granneman","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0070","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/tx950216s","article-title":"Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect","volume":"9","author":"Bojic","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0014-2999(98)00462-2","article-title":"Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic centre","volume":"354","author":"Bojic","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0080","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/(SICI)1096-9888(199608)31:8<926::AID-JMS383>3.0.CO;2-P","article-title":"Characterization of thiol-conjugated metabolites of 2-propyl-4-pentenoic acid (4-ene-VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry","volume":"13","author":"Tang","year":"1996","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-199120020-00003","article-title":"Clinical pharmacology of valpromide","volume":"20","author":"Bialer","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0090","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1023\/A:1016277507865","article-title":"Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine","volume":"12","author":"Hadad","year":"1995","journal-title":"Pharm Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0095","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1012009012850","article-title":"Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives","volume":"14","author":"Levi","year":"1997","journal-title":"Pharm Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00019052-200304000-00014","article-title":"New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?","volume":"16","author":"Isoherranen","year":"2003","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0306-3623(84)90018-1","article-title":"Synergistic anticonvulsant effects of a gaba agonist and glycine","volume":"15","author":"Seiler","year":"1984","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0110","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/BF00968081","article-title":"Glycine potentiates the action of some anticonvulsant drugs in some seizure models","volume":"9","author":"Toth","year":"1984","journal-title":"Neurochem Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0014-2999(90)90498-U","article-title":"Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine","volume":"182","author":"Liu","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0120","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1528-1157.2001.042007831.x","article-title":"Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug","volume":"42","author":"Isoherranen","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/(SICI)1099-081X(199710)18:7<557::AID-BDD48>3.0.CO;2-D","article-title":"Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide","volume":"18","author":"Hadad","year":"1997","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0130","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1517\/13543784.11.10.1387","article-title":"Novel anticonvulsant medications in development","volume":"11","author":"Hovinga","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2006.10.008","article-title":"Progress report on new antiepileptic drugs: a summary of the eighth Eilat conference (Eilat VIII)","volume":"73","author":"Bialer","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0140","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nurt.2006.11.007","article-title":"Valproic acid: second generation","volume":"4","author":"Bialer","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00315032","article-title":"Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.","volume":"38","author":"Bialer","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0150","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0009-9236(97)90194-6","article-title":"Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy","volume":"61","author":"Barel","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0155","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial","volume":"12","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0160","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/jps.2600771003","article-title":"Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs","volume":"77","author":"Haj-Yehia","year":"1988","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0165","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1023\/A:1015862613315","article-title":"Pharmacokinetic analysis of the structural requirements for forming \"stable\" analogues of valpromide","volume":"9","author":"Haj-Yehia","year":"1992","journal-title":"Pharm Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF01870931","article-title":"Can we develop improved derivatives of valproic acid?","volume":"16","author":"Bialer","year":"1994","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0175","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.neuropharm.2010.03.004","article-title":"Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid","volume":"52","author":"Kaufmann","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0180","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1021\/jm900017f","article-title":"Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid","volume":"52","author":"Pessah","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0185","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1021\/jm0498351","article-title":"Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. synthesis and evaluation of anticonvulsant activity of its amide derivatives","volume":"47","author":"Sobol","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eplepsyres.2006.08.004","article-title":"Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide","volume":"73","author":"Sobol","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0195","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.1528-1167.2008.01624.x","article-title":"Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid","volume":"49","author":"Shimshoni","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0200","series-title":"Antiepileptic drugs","first-page":"36","article-title":"Discovery and preclinical development of antiepileptic drugs","author":"White","year":"2002"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation: II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0210","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/tera.1420380403","article-title":"Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite","volume":"38","author":"Finnell","year":"1988","journal-title":"Teratology"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0215","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/(SICI)1096-8628(19970613)70:3<303::AID-AJMG17>3.0.CO;2-P","article-title":"Strain dependent alteration in the expression of folate pathway genes following teratogenic exposure to valproic acid in mouse model","volume":"70","author":"Finnell","year":"1997","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0220","first-page":"401","article-title":"Challenges in the search for drugs to treat central nerve systems disorders","volume":"329","author":"Emma","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0225","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1365-2044.2001.02115.x","article-title":"Status epilepticus","volume":"56","author":"Chapman","year":"2001","journal-title":"Anaesthesia"},{"issue":"Suppl. 6","key":"10.1016\/j.yebeh.2011.08.026_bb0230","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1111\/j.1528-1157.1996.tb06037.x","article-title":"The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome","volume":"37","author":"Morrell","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2011.08.026_bb0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2006.02.004","article-title":"Diverse mechanisms of antiepileptic drugs in the development pipeline","volume":"69","author":"Rogawski","year":"2006","journal-title":"Epilepsy Res"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505011004902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505011004902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:22:38Z","timestamp":1543519358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505011004902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1525505011004902"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2011.08.026","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}